KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday

KALA BIO (NASDAQ:KALA) is projected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($2.28) per share for the quarter.

KALA BIO Trading Down 3.8 %

Shares of KALA stock opened at $6.32 on Friday. KALA BIO has a 1-year low of $4.21 and a 1-year high of $11.20. The firm has a market cap of $38.50 million, a PE ratio of -0.51 and a beta of -2.19. The company has a 50-day moving average of $7.72 and a two-hundred day moving average of $6.80. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Thursday, February 13th.

Insider Activity at KALA BIO

In other KALA BIO news, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the acquisition, the insider now owns 1,083,398 shares of the company’s stock, valued at approximately $6,977,083.12. This trade represents a 40.18 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark T. Iwicki sold 5,779 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the sale, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,506 shares of company stock worth $72,531. 8.32% of the stock is currently owned by company insiders.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.